Development Drug Delivery Drugs In-Vitro 
Drug Discovery World
OCTOBER 19, 2022
Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . This journey is far from straightforward.
The Pharma Data
OCTOBER 27, 2020
The test is planned for commercial launch as a CE-IVD ( in vitro diagnostic) certified product in the European Union in Q1 2021. “Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. . About XPhyto Therapeutics Corp.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
FEBRUARY 18, 2021
Maculus plans to raise USD3 million on a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies. Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc.
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale? I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.
The Pharma Data
JANUARY 16, 2021
It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. Etta Biotech is a leading cell electroporation technology and equipment supplier. About Etta Biotech.
pharmaphorum
DECEMBER 15, 2022
Oxsonics Therapeutics, which offers an ultrasound-based drug delivery platform, appointed Jérôme Marzinski, a board member at Cimon Medical and former CEO of ophthalmic diagnostic company Visiometrics into its top job. The month of November saw a number of notable hires and personnel moves in biotech and pharma. More CEO shakeups.
Drug Discovery World
AUGUST 3, 2022
Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake.
Expert insights. Personalized for you.
52 
Let's personalize your content